论文部分内容阅读
目的分析胃癌合并糖尿病患者术后早期肠内营养的临床效果。方法将43例胃癌合并糖尿病患者术后随机分为两组:23例肠内营养(EN)组和20例肠外营养(TPN)组。EN组手术后48 h内经鼻空肠营养管输注肠内营养乳剂(TPF-D)(商品名:瑞代),TPN组经颈内静脉置深静脉导管静滴,共8 d。结果EN组术后10 d体质量损失较TPN组明显减少,差异有高度统计学意义(P<0.01);平均血糖波动值降低,肛门排气时间短,相关并发症以及营养相关费用降低,差异均有统计学意义(P<0.05);其他情况比较,差异无统计学意义(P>0.05)。结论胃癌合并糖尿病患者术后EN支持营养疗效好,肠功能恢复快,并发症少,血糖波动小,住院费用低,安全可靠。
Objective To analyze the clinical effect of early enteral nutrition in patients with gastric cancer complicated with diabetes mellitus. Methods Forty-three gastric cancer patients with diabetes were randomly divided into two groups: 23 enteral nutrition (EN) group and 20 parenteral nutrition (TPN) group. The enteral nutrition emulsion (TPF-D) (brand name: Ruidei) was infused via nasogastric feeding tube within 48 hours after operation in EN group. The TPN group was intravenously administered with deep vein catheter through internal jugular vein for 8 days. Results The body weight loss of EN group was significantly lower than that of TPN group at 10 d after operation (P <0.01), the mean blood glucose fluctuation value was decreased, the time of anus exhaust was short, the related complications and nutrition-related costs were reduced. (P <0.05). In other cases, the difference was not statistically significant (P> 0.05). Conclusions EN patients with gastric cancer complicated with diabetes have better nutrition support, faster recovery of intestinal function, fewer complications, less fluctuation of blood glucose, lower hospitalization costs, and safety and reliability.